RARG and metabolic dysfunction-associated steatotic liver disease: We discovered that a selective RARβ2 agonist attenuates the increases in the expression of pro-inflammatory mediators in NAFLD mouse models, including TNFα, CCL2, CCR2, and IL1β, while a RARγ agonist has no effect [90,94] (Figure 2).